Synergy Pharma (SGYP) Misses Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Synergy Pharmaceuticals Reports Second Quarter and First Half 2015 Financial Results and Business Update
August 10, 2015 4:30 PM EDTReported positive top-line data results in both phase 3 clinical trials of plecanatide in patients with chronic idiopathic constipation (CIC) Company on-track for first NDA filing with plecanatide for CIC in January 2016 Continued to advance the plecanatide phase 3 program for irritable bowel syndrome with constipation (IBS-C)
NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company focused... More
